Rapid response of a cardiac rhabdomyoma causing severe right ventricular outflow obstruction to Sirolimus in an infant with negative genetics for Tuberous sclerosis.

Abstract

Mammalian target of rapamycin inhibitors was found recently to be an effective treatment for manifestations of Tuberous sclerosis complex, including cardiac rhabdomyomas. Most cases with Cardiac rhabdomyoma treated with mammalian target of rapamycin inhibitors to date were diagnosed with Tuberous sclerosis. We report a case of cardiac rhabdomyoma and severe right ventricular outflow obstruction in a baby with negative genetics for Tuberous sclerosis that responded rapidly to Sirolimus.

• Authors: Yifat Nir-David, Sharon Brosilow, Asaad Khoury
• Journal: Cardiology in the young (Cardiol Young) Vol. 31 Issue 2 Pg. 312-314 (Feb 2021) ISSN: 1467-1107 [Electronic] England
• PMID: 33148352 (Publication Type: Case Reports, Journal Article)

Chemical References

• Sirolimus

Topics

• Heart Neoplasms (complications, diagnosis, drug therapy)
• Humans
• Infant
• Rhabdomyoma (complications, diagnosis, drug therapy)
• Sirolimus (therapeutic use)
• Tuberous Sclerosis (complications, diagnosis, drug therapy)
• Ventricular Outflow Obstruction (etiology)